Epclusa

sofosbuvir/velpatasvir (SOF/VEL)

FDA approved for HIV/HCV co-infection
Genotype
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

One tablet once daily with or without food. Pellets for pediatric use are available. Treatment is usually 12 weeks, but ribavirin may be added, or treatment may be extended to 24 weeks for certain patients.

Each tablet used for adults contains 400 mg of sofosbuvir and 100 mg of velpatasvir. New oral pellet formulations were approved in June 2021 (200 mg SOF/50 mg VEL or 150 mg SOF/37.5 mg VEL), which allows dosing in children at least 3 years old (as opposed to 6 years and older previously) and weighing at least 17 kg.

The brand name is dispensed in a bottle; the authorized generic is dispensed in a blister pack. The authorized generic was created to help lower cost and has identical ingredients as the brand name.

Take your missed dose as soon as possible unless it is less than 12 hours until your next dose. Do not double up on your next dose.

Manufacturer

BRAND: Gilead Sciences
AUTHORIZED GENERIC: Asegua Therapeutics LLC

AWP

BRAND (400/100 mg and 250/50 mg tablets): $29,904 / month
AUTHORIZED GENERIC (400/100 mg tablets only): $9,600 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information